132 related articles for article (PubMed ID: 12678804)
1. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
[TBL] [Abstract][Full Text] [Related]
2. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
3. Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds.
Campos JM; Núñez MC; Sánchez RM; Gómez-Vidal JA; Rodríguez-González A; Báñez M; Gallo MA; Lacal JC; Espinosa A
Bioorg Med Chem; 2002 Jul; 10(7):2215-31. PubMed ID: 11983519
[TBL] [Abstract][Full Text] [Related]
4. (Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs.
Campos JM; Sánchez-Martín RM; Conejo-García A; Entrena A; Gallo MA; Espinosa A
Curr Med Chem; 2006; 13(11):1231-48. PubMed ID: 16712467
[TBL] [Abstract][Full Text] [Related]
5. Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1"-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted)amino]pyridinium] tribromides.
Conejo-García A; Campos J; Sánchez RM; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Eur J Med Chem; 2003 Jan; 38(1):109-16. PubMed ID: 12593921
[TBL] [Abstract][Full Text] [Related]
6. New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
[TBL] [Abstract][Full Text] [Related]
7. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.
Conejo-García A; Báñez-Coronel M; Sánchez-Martín RM; Rodríguez-González A; Ramos A; Ramírez de Molina A; Espinosa A; Gallo MA; Campos JM; Lacal JC
J Med Chem; 2004 Oct; 47(22):5433-40. PubMed ID: 15481981
[TBL] [Abstract][Full Text] [Related]
8. Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors.
Conejo-García A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
J Med Chem; 2003 Aug; 46(17):3754-7. PubMed ID: 12904080
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of new bispyridinium salts of 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazoles.
Martín-Cantalejo Y; Sáez B; Monterde MI; Murillo MT; Braña MF
Eur J Med Chem; 2011 Nov; 46(11):5662-7. PubMed ID: 21996467
[TBL] [Abstract][Full Text] [Related]
10. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase.
Campos J; del Carmen Núñez M; Rodríguez V; Entrena A; Hernández-Alcoceba R; Fernández F; Lacal JC; Gallo MA; Espinosa A
Eur J Med Chem; 2001 Mar; 36(3):215-25. PubMed ID: 11337100
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
12. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line.
Gómez-Pérez V; McSorley T; See Too WC; Konrad M; Campos JM
ChemMedChem; 2012 Apr; 7(4):663-9. PubMed ID: 22278967
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.
Hong BS; Allali-Hassani A; Tempel W; Finerty PJ; Mackenzie F; Dimov S; Vedadi M; Park HW
J Biol Chem; 2010 May; 285(21):16330-40. PubMed ID: 20299452
[TBL] [Abstract][Full Text] [Related]
14. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.
Sánchez-Martín R; Campos JM; Conejo-García A; Cruz-López O; Báñez-Coronel M; Rodríguez-González A; Gallo MA; Lacal JC; Espinosa A
J Med Chem; 2005 May; 48(9):3354-63. PubMed ID: 15857141
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.
Rubio-Ruíz B; Conejo-García A; Ríos-Marco P; Carrasco-Jiménez MP; Segovia J; Marco C; Gallo MA; Espinosa A; Entrena A
Eur J Med Chem; 2012 Apr; 50():154-62. PubMed ID: 22348828
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
17. Choline kinase: an important target for cancer.
Janardhan S; Srivani P; Sastry GN
Curr Med Chem; 2006; 13(10):1169-86. PubMed ID: 16719778
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Rodríguez-González A; Ramírez de Molina A; Fernández F; Ramos MA; del Carmen Núñez M; Campos J; Lacal JC
Oncogene; 2003 Dec; 22(55):8803-12. PubMed ID: 14654777
[TBL] [Abstract][Full Text] [Related]
19. Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases.
Lacal JC; Zimmerman T; Campos JM
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34070409
[TBL] [Abstract][Full Text] [Related]
20. A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.
Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Lacal JC
Clin Transl Oncol; 2015 Jan; 17(1):74-84. PubMed ID: 25472447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
